BridgeBio Pharma, Inc.
NASDAQ:BBIOBiotechnology
+$0.75 today
- Market cap
- $15.20B
- Beta
- 0.97
- P/E (TTM)
- -18.1
- EPS (TTM)
- -$3.73
Volume 3.55M
Average 2.49M
BBIO Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
BridgeBio Pharma, Inc.NASDAQ: BBIO
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q2 FY2026 stock-based compensation of $44.07M rose 18.3% year over year, ahead of the -7.0% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 32.6% from the prior quarter. Over 3 fiscal years it compounded at +13.3% a year.
Context
- Stock-based compensation amounted to 26.5% of revenue in FY2025, down 16.7 pp from a year earlier.
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +18.3% holds above the trailing-twelve-month pace of -7.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 133.02M USD
- Year-over-year change
- +38.9%
- 4-year CAGR
- +7.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 133.02M | +38.9% |
| FY2024 | 2024-12-31 | 95.8M | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 91.56M | -8.0% |
| FY2021 | 2021-12-31 | 99.51M | — |
Stock-Based Compensation vs competitors
How BBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -7.0% is the 9th highest of 11, against a peer median of +14.8%.
- Stock-based compensation amounts to 15.7% of revenue for BBIO, versus a peer median of 15.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $172.73B USD | +92559.3% | -2.6% | 16.8% | |
| LTM Jun 2026 | $336.62M USD | +10.1% | +14.7% | 7.0% | |
| LTM Mar 2026 | $142.83M USD | -11.3% | +5.5% | 21.3% | |
| LTM Sep 2026 | $132.29M USD | +4.4% | +10.1% | 13.8% | |
| LTM Jun 2026 | $111.95M USD | -7.0% | +13.3% | 15.7% | |
| LTM Jun 2026 | $84.66M USD | +15.0% | -12.3% | 8.4% | |
| LTM Sep 2026 | $75.24M USD | +14.6% | +39.7% | 13200.2% | |
| LTM Sep 2026 | $72.84M USD | +70.9% | +5.6% | 11.2% | |
| LTM Jun 2026 | $69.95M USD | +39.2% | -0.1% | 1941.0% | |
| LTM Mar 2026 | $20.28M USD | +92.0% | +34.5% | 101.4% | |
| LTM Sep 2026 | €0 EUR | -100.0% | — | 0.0% | |
| Peer median (excluding BBIO) | — | +14.8% | +5.6% | 15.3% | |
Competitors are the stored peer set for BBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (586.45M) | (484.65M) | (643.2M) | (543.35M) | (724.93M) |
| Depreciation & Amortization | 5.84M | 6.77M | 6.49M | 6.08M | 5.43M |
| Deferred Income Tax | (30.93M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 99.51M | 91.56M | 0 | 95.8M | 133.02M |
| Change in Working Capital | (4.4M) | 28.08M | 5.06M | 32.04M | (51.06M) |
| Accounts Receivables | (19.75M) | 15.17M | 15.33M | (2.97M) | (134.72M) |
| Inventory | 19.75M | 0 | 0 | 0 | (25.31M) |
| Accounts Payables | 2.83M | (349K) | 2.78M | 1.51M | 26.61M |
| Other Working Capital | (7.23M) | 13.26M | (13.05M) | 33.5M | 82.36M |
| Other Non-Cash Items | 18.5M | (61.25M) | 103.93M | (111.3M) | 191.63M |
| Operating Cash Flow | (497.93M) | (419.49M) | (527.72M) | (520.73M) | (445.91M) |
| Capital Expenditures | (48.25M) | (6.32M) | (1.31M) | (933K) | (1.1M) |
| Acquisitions (Net) | (35M) | 0 | 0 | (140K) | 0 |
| Purchases of Investments | (643.28M) | (193.06M) | (137.26M) | (88.4M) | (28.2M) |
| Sales of Investments | 477.04M | 532.52M | 193.11M | 158.23M | 11M |
| Other Investing Activities | 48.65M | 118.5M | (503K) | (7.98M) | (6.19M) |
| Investing Cash Flow | (200.83M) | 453.15M | 54.03M | 60.78M | (24.49M) |
| Debt Repayment | 1.08B | (20.49M) | 0 | 476.58M | 385.5M |
| Common Stock Issued | 0 | 4.85M | 449.81M | 314.74M | 34.15M |
| Common Stock Repurchased | (204.75M) | (1.56M) | (6.88M) | (7.53M) | (48.28M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (138.49M) | 4.06M | 8.61M | (35.34M) | (12.08M) |
| Financing Cash Flow | 736.45M | (13.13M) | 451.54M | 748.46M | 359.29M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 37.69M | 20.52M | (22.15M) | 288.51M | (111.1M) |
| Free Cash Flow | (546.18M) | (425.82M) | (529.03M) | (521.66M) | (447.01M) |
BridgeBio Pharma, Inc.
NASDAQ:BBIO
Intrinsic Alpha fair value
Locked
Current Price
$78.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.